Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

First Line ◽

Castration Resistant ◽

Randomized Phase Ii ◽

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-010-1389-7 ◽

2010 ◽

Vol 67 (4) ◽

pp. 927-933 ◽

Cited By ~ 15

Author(s):

Srikala S. Sridhar ◽

Christina M. Canil ◽

Kim N. Chi ◽

Sebastien J. Hotte ◽

Scott Ernst ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Antisense Oligonucleotide ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Castration Resistant ◽

7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71414-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 417

Author(s):

A. Fontana ◽

L. Galli ◽

L. Derosa ◽

G. Minuti ◽

M. D'Arcangelo ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Castration Resistant ◽

Metronomic Cyclophosphamide ◽

565 POSTER Activity of the anti-IGF-IR antibody CP-751,871 in combination with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72499-6 ◽

2008 ◽

Vol 6 (12) ◽

pp. 178 ◽

Cited By ~ 1

Author(s):

J.S. De Bono ◽

D.P. Petrylak ◽

E. Calvo ◽

F. Saad ◽

G.R. Hudes ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.016 ◽

2021 ◽

Vol 155 ◽

pp. 56-63

Author(s):

Orazio Caffo ◽

Cinzia Ortega ◽

Franco Nolè ◽

Donatello Gasparro ◽

Claudia Mucciarini ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Castration Resistant ◽

P118 Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)

European Urology Supplements ◽

10.1016/s1569-9056(13)60484-4 ◽

2012 ◽

Vol 11 (5) ◽

pp. 231-232

Author(s):

O. Caffo ◽

G. Lo Re ◽

T. Sava ◽

S. Buti ◽

C. Sacco ◽

...

Keyword(s):

Prostate Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

Castration Resistant ◽

Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment—ABIDO-SOGUG Trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e16022 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e16022-e16022 ◽

Cited By ~ 1

Author(s):

Ignacio Duran ◽

Enrique Grande ◽

Daniel E. Castellano ◽

Albert Font ◽

M Isabel Sáez ◽

...

Keyword(s):

Prostate Cancer ◽

Disease Progression ◽

Phase Ii ◽

Phase Ii Study ◽

Abiraterone Acetate ◽

First Line ◽

Castration Resistant ◽

Randomized Phase Ii

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Cited By ~ 58

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

European Urology ◽

10.1016/j.eururo.2007.02.060 ◽

2007 ◽

Vol 52 (4) ◽

pp. 1020-1027 ◽

Cited By ~ 13

Author(s):

Giuseppe Di Lorenzo ◽

Riccardo Autorino ◽

Sisto Perdonà ◽

Michele De Laurentiis ◽

Massimo D'Armiento ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Line Treatment ◽

First Line ◽

Hormone Refractory ◽

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

10.1158/1538-7445.am2014-ct101 ◽

2014 ◽

Cited By ~ 23

Author(s):

Richard S. Finn ◽

John P. Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Randomized Phase Ii ◽

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽